BioMarin Pharmaceutical Inc. Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN RAFAEL, Calif., June 3, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors. BMN 673 has exhibited substantial single-agent anti-tumor activity in deleterious germline BRCA ovarian and breast cancers in the trial. The data were presented during a poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting.

Help employers find you! Check out all the jobs and post your resume.

Back to news